APPLICATION for ORPHAN MEDICINAL PRODUCT DESIGNATION

DECLARATION and SIGNATURE

Name of the active substance(s): 

Sponsor: 

It is hereby confirmed that all data required for the designation of this medicinal product as an orphan medicinal product have been included in the dossier.

It is hereby confirmed that the summaries provided in the application are an accurate account of the data obtained by the sponsor.

________________________________________________________
(Signature(s) and function of sponsor)

_________________
(Place and date)
This application form is to be used to apply for the designation of a medicinal product for human use as an orphan medicinal product, according to Regulation (EC) No 141/2000 of 16 December 1999 and Commission Regulation ....... The application should be submitted to the European Agency for the Evaluation of Medicinal Products (EMEA). The sponsor should await confirmation from the EMEA that the application has been successfully validated, before submitting it to the Committee for Orphan Medicinal Products.

NOTE: PLEASE CONSULT THE ‘GUIDELINE FOR THE FORMAT AND CONTENT OF APPLICATIONS FOR DESIGNATION AS ORPHAN MEDICINAL PRODUCTS (ENTR/6283/00)’ WHEN COMPLETING THIS FORM.

I. CRITERIA FOR DESIGNATION

Note: The following sections should be ticked (√) and completed as appropriate.

I.1. THIS APPLICATION CONCERNS:

Note: A sponsor requesting designation of a medicinal product as an orphan medicinal product must request designation before an application for marketing authorisation is made. A request for designation may, however, be made for a new indication for an already authorised medicinal product.

☐ I.1.1. AN ACTIVE SUBSTANCE NOT CURRENTLY AUTHORISED IN THE COMMUNITY

☐ I.1.2. AN ACTIVE SUBSTANCE CURRENTLY AUTHORISED IN THE COMMUNITY

Note: The indication for which orphan designation is sought in this application must be different to that currently authorised.

If you are the holder of an existing marketing authorisation in the Community for this product, please provide details of the currently authorised indication and the type of marketing authorisation below:

I.1.2.1 Authorised indication(s)

I.1.2.2 Type of marketing authorisation (tick and complete as appropriate)

☒ CENTRALISED (according to Council regulation EEC No 2309/93)

Tradename: ..............................................................................................................................

Date of authorisation: ........................................................

Marketing authorisation number(s): ..........................................................

Marketing authorisation holder: ..............................................................................
☐ MUTUAL RECOGNITION (according to Art. 9 of Dir. 75/319/EEC as amended)

Reference Member State: ..............................................................................................................
Date of authorisation: ......................................................................................................................
Marketing authorisation holder: ........................................................................................................
Concerned Member State(s) (specify):

☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐
AT BE DE DK EL ES FI FR IR IT LU NL PT SE UK

Please attach details of tradename(s) and marketing authorisation number(s)

☐ NATIONAL PROCEDURE

Member State(s) where authorised (specify):

☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐
AT BE DE DK EL ES FI FR IR IT LU NL PT SE UK

Marketing authorisation holder: ........................................................................................................
Please attach details of tradename(s) and marketing authorisation number(s)

I.2. THIS APPLICATION IS IN ACCORDANCE WITH THE FOLLOWING PARAGRAPHS IN ARTICLE 3, REGULATION (EC) 141/2000

Note: Both sections I.2.1 and I.2.2 should be completed for all designation applications, by ticking (√) as appropriate.

I.2.1. ARTICLE 3(1)(a), PARAGRAPHS 1 OR 2

☐ PARAGRAPH 1 - PREVALENCE OF A CONDITION IN THE COMMUNITY

Note: For the documentation submitted in support of this application (see Table of Contents p.8). Sections A(1-3); B(1), B(3) should be completed.

☐ PARAGRAPH 2 - POTENTIAL FOR RETURN ON INVESTMENT

Note: For the documentation submitted in support of this application (see Table of Contents p.8). Sections A(1-3); B(2-3); C(1-5) should be completed.

I.2.2. ARTICLE 3(1)(b), EXISTENCE OF OTHER METHODS OF DIAGNOSIS, PREVENTION OR TREATMENT

☐ NO OTHER METHODS EXIST IN THE COMMUNITY

Note: For the documentation submitted in support of this application (see Table of Contents p.8). Section D(1) should contain a statement that no other methods currently exist.

☐ OTHER METHODS EXIST BUT ARE NOT CONSIDERED SATISFACTORY

Note: For the documentation submitted in support of this application (see Table of Contents p.8). Sections D(1) and D (2) should be completed.

☐ OTHER SATISFACTORY METHODS EXIST BUT THIS MEDICINAL PRODUCT WILL BE OF SIGNIFICANT BENEFIT TO THOSE AFFECTED BY THE CONDITION

Note: For the documentation submitted in support of this application (see Table of Contents p.8). Section D(1) and D (3) should be completed
II. DESIGNATION APPLICATION PARTICULARS

II.1. Name

II.1.1 Name of the active substance(s):

Note: Only one name should be given in the following order of priority: INN\(^1\), Ph.Eur., National Pharmacopoeia, common name, scientific name

II.2. Proposed indication and ATC code

II.2.1 Proposed indication:

Note: If more than one indication is applied for, separate applications should be submitted for each indication. The dossier should contain a more detailed description of the condition in Section A and a summary of the development of the product in Section E (see Table of Contents for Remainder of Dossier p.8)

II.2.2 Pharmacotherapeutic group (Please use current ATC code if known):

ATC Code: ___________________ Group: ___________________

Please indicate when the ATC Code is pending

II.3. Tradename, Strength, pharmaceutical form and route of administration

Note: For products that are in the early stages of development it may not be possible to complete this section.

II.3.1 Proposed Tradename of the medicinal product in the Community/Member States(s):

II.3.2 Strength(s) and Pharmaceutical form(s) (use current list of standard terms - European Pharmacopoeia)

Strength(s) ___________________ Ph. Form(s) ___________________

\(^1\) The INN should be accompanied by its salt or hydrate form if relevant
II.3.3 Proposed route(s) of administration (use current list of standard terms - European Pharmacopoeia)

II.4. Sponsor / Contact person

II.4.1 Sponsor:

Name or corporate name of sponsor:
Address:
Country:
Telephone:
Telefax:
E-Mail:

Attach proof of establishment of the sponsor in the EEA

II.4.2 For sponsors whose main business is operated from outside the Community, address of those premises and a contact name

Name or corporate name of sponsor:
Contact name:
Address:
Country:
Telephone:
Telefax:
E-Mail:

II.4.3 Person/company responsible for research and development of the medicinal product, if different from II.4.1:

Name or corporate name:
Address:
Country:
Telephone:
Telefax:
E-Mail:
**II.4.4 Person/company authorised for communication on behalf of the sponsor during the procedure:**

Name of contact:  
Address:  
Country:  
Telephone:  
Telefax:  
E-Mail:  

☐ If different to II.4.1 above,  
Append a letter of authorisation

**II.4.5 Person/company for communication between the sponsor and the Agency after designation if different from II.4.1:**

Name:  
Address:  
Country:  
Telephone:  
Telefax:  
E-Mail:  

☐ If different to II.4.1 above,  
Append a letter of authorisation

**II.5 Manufacturers**

*Note: For products that are in the early stages of development it may not be possible to complete section II.5.2.*

**II.5.1 Name of Manufacturer(s) and site(s) of manufacture of the active substance(s):**

Name:  
Address:  
Country:  
Telephone:  
Telefax:  
E-Mail:

**II.5.2 Name of Manufacturer(s) and site(s) of manufacture of the finished medicinal product:**

Name:  
Address:  
Country:  
Telephone:  
Telefax:  
E-Mail
III OTHER INFORMATION

III.1 Scientific Advice:

III.1.1 Has scientific advice been given by the CPMP for this medicinal product?

☐ yes  ☐ no

If yes,

Date:
Reference of the scientific advice letter:
Append a copy of the scientific advice letter

III.2 Protocol assistance:

III.2.1 Do you intend to seek protocol assistance for this medicinal product?

☐ yes  ☐ no

If yes, when?

III.3 Application for Marketing Authorisation:

III.3.1 Details of planned submission of application for marketing authorisation *(if known)*?

Planned submission date:

Intended route of submission:  ☐ Centralised  ☐ Mutual Recognition

Do you intend to request a fee reduction?  ☐ yes  ☐ no
This table of contents/checklist is to be used as a guide to complete the documentation to be submitted in an application for designation of a medicinal product for human use as an orphan medicinal product, according to Regulation (EC) No 141/2000 of 16 December 1999 and Commission Regulation ........

NOTE: PLEASE CONSULT THE ‘GUIDELINE FOR THE FORMAT AND CONTENT OF APPLICATIONS FOR DESIGNATION AS ORPHAN MEDICINAL PRODUCTS (ENTR/6283/00)’ WHEN PREPARING THE APPLICATION.

### SECTION A) DESCRIPTION OF THE CONDITION

<table>
<thead>
<tr>
<th>INDEX</th>
<th>CHECKLIST (tick ☐, as appropriate)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Page___ to ___</td>
<td>Page___ to ___</td>
</tr>
</tbody>
</table>

1. Details of the condition.  ☐ Included
2. Proposed therapeutic indication.  ☐ Included
3. Medical plausibility.  ☐ Included  ☐ Not Applicable
4. Justification of the life-threatening or debilitating nature of the condition.  ☐ Included

Note:  
- Section A(1-2) and A(4) should be completed for all applications.
- Section A(3) should be completed if applicable.

### SECTION B) PREVALENCE OF THE CONDITION

<table>
<thead>
<tr>
<th>INDEX</th>
<th>CHECKLIST (tick ☐, as appropriate)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Page___ to ___</td>
<td>Page___ to ___</td>
</tr>
</tbody>
</table>

1. Prevalence of the orphan disease or condition in the Community.  ☐ Included  ☐ Not Applicable
2. Prevalence and incidence of the condition in the Community.  ☐ Included  ☐ Not Applicable
3. Information on participation in other Community projects.  ☐ Included

Note:  
- Section B (1) should be completed for applications submitted in accordance with Article 3(1)(a) paragraph 1
- Section B (2) should be completed for applications submitted in accordance with Article 3(1)(a) paragraph 2
- Section B (3) should be completed for all applications
## SECTION C) POTENTIAL FOR RETURN ON INVESTMENT

<table>
<thead>
<tr>
<th>INDEX</th>
<th>CHECKLIST (tick □, as appropriate)</th>
<th>INDEX</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>□ Included</td>
<td>□ Not Applicable</td>
</tr>
<tr>
<td></td>
<td>2. Past and future development costs.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>□ Included</td>
<td>□ Not Applicable</td>
</tr>
<tr>
<td></td>
<td>3. Production and marketing costs.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>□ Included</td>
<td>□ Not Applicable</td>
</tr>
<tr>
<td></td>
<td>4. Expected revenues</td>
<td></td>
</tr>
<tr>
<td></td>
<td>□ Included</td>
<td>□ Not Applicable</td>
</tr>
<tr>
<td></td>
<td>5. Certification by registered accountant.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>□ Included</td>
<td>□ Not Applicable</td>
</tr>
</tbody>
</table>

Note: - This section should only be completed for applications submitted in accordance with Article 3(1)(a) para 2

## SECTION D) OTHER METHODS FOR DIAGNOSIS, PREVENTION OR TREATMENT OF THE CONDITION

<table>
<thead>
<tr>
<th>INDEX</th>
<th>CHECKLIST (tick □, as appropriate)</th>
<th>INDEX</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1. Details of any existing diagnosis, prevention or treatment methods.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>□ Included</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2. Justification as to why the methods are not considered satisfactory.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>□ Included</td>
<td>□ Not Applicable</td>
</tr>
<tr>
<td></td>
<td>3. Justification of significant benefit.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>□ Included</td>
<td>□ Not Applicable</td>
</tr>
</tbody>
</table>

Note: - Section D (1) should be completed for all applications
- Section D (2) or D (3) should be completed as appropriate.

## SECTION E) DESCRIPTION OF THE STAGE OF DEVELOPMENT

<table>
<thead>
<tr>
<th>INDEX</th>
<th>CHECKLIST (tick □, as appropriate)</th>
<th>INDEX</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1. Summary of the development of the product.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>□ Included</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2. Details of regulatory status and marketing history in non EU countries.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>□ Included</td>
<td></td>
</tr>
</tbody>
</table>

Note: - This section should be completed for all applications.

## SECTION F) BIBLIOGRAPHY

<table>
<thead>
<tr>
<th>INDEX</th>
<th>CHECKLIST (tick □, as appropriate)</th>
<th>INDEX</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>This section should contain all published references referred to in the sections A to D above.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>□ Included</td>
<td></td>
</tr>
</tbody>
</table>